Jeff Johnson
Stock Analyst at Baird
(4.69)
# 170
Out of 4,893 analysts
143
Total ratings
60.2%
Success rate
30.58%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
COO The Cooper Companies | Maintains: Outperform | $107 → $97 | $75.34 | +28.75% | 17 | May 30, 2025 | |
NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $20.34 | +13.08% | 10 | May 27, 2025 | |
ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $93.77 | +22.64% | 14 | May 6, 2025 | |
DXCM DexCom | Maintains: Outperform | $115 → $105 | $84.04 | +24.94% | 14 | May 2, 2025 | |
TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $15.84 | +51.52% | 16 | May 1, 2025 | |
ALC Alcon | Maintains: Outperform | $104 → $108 | $87.83 | +22.96% | 9 | Feb 27, 2025 | |
BBNX Beta Bionics | Initiates: Neutral | $20 | $13.55 | +47.63% | 1 | Feb 20, 2025 | |
SYK Stryker | Maintains: Outperform | $378 → $405 | $391.15 | +3.54% | 11 | Oct 30, 2024 | |
ALGN Align Technology | Maintains: Outperform | $325 → $276 | $201.95 | +36.67% | 18 | Oct 24, 2024 | |
HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $73.24 | +11.97% | 9 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $294.64 | -19.22% | 12 | Dec 21, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $34.81 | +101.09% | 2 | Aug 4, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.81 | +311.88% | 4 | Jul 28, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $16.30 | +311.04% | 6 | Feb 18, 2022 |
The Cooper Companies
May 30, 2025
Maintains: Outperform
Price Target: $107 → $97
Current: $75.34
Upside: +28.75%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $20.34
Upside: +13.08%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $93.77
Upside: +22.64%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $84.04
Upside: +24.94%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $15.84
Upside: +51.52%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $87.83
Upside: +22.96%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $13.55
Upside: +47.63%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $391.15
Upside: +3.54%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $201.95
Upside: +36.67%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $73.24
Upside: +11.97%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $294.64
Upside: -19.22%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $34.81
Upside: +101.09%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.81
Upside: +311.88%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $16.30
Upside: +311.04%